Alamar Biosciences (NASDAQ:ALMR) Price Target Raised to $36.00

Alamar Biosciences (NASDAQ:ALMR) had its price objective upped by analysts at TD Cowen from $34.00 to $36.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen‘s price objective suggests a potential upside of 32.50% from the stock’s current price.

A number of other equities analysts have also commented on the stock. Stifel Nicolaus boosted their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings cut Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Finally, JPMorgan Chase & Co. increased their price target on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $33.00.

Alamar Biosciences Price Performance

NASDAQ:ALMR traded down $3.05 during trading hours on Wednesday, reaching $27.17. 855,957 shares of the company traded hands, compared to its average volume of 426,738. The firm’s 50-day simple moving average is $30.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.23 and a current ratio of 11.85. The stock has a market capitalization of $1.89 billion and a PE ratio of -13.86. Alamar Biosciences has a 1-year low of $18.84 and a 1-year high of $39.61.

Alamar Biosciences (NASDAQ:ALMR) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. The business had revenue of $33.55 million for the quarter. As a group, research analysts predict that Alamar Biosciences will post -1.22 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65. Following the transaction, the insider owned 174,677 shares of the company’s stock, valued at $5,294,459.87. This trade represents a 54.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,387,636 shares of company stock worth $41,234,931 in the last 90 days.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALMR. China Universal Asset Management Co. Ltd. acquired a new stake in Alamar Biosciences in the 3rd quarter worth $196,000. Squarepoint Ops LLC bought a new position in Alamar Biosciences in the 2nd quarter valued at $283,000. Sumitomo Mitsui Trust Group Inc. increased its position in Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after acquiring an additional 10,461 shares in the last quarter. State Street Corp bought a new position in Alamar Biosciences in the 2nd quarter valued at $3,930,000. Finally, Wellington Management Group LLP bought a new stake in Alamar Biosciences during the 2nd quarter worth about $12,407,000.

Key Headlines Impacting Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported a third-quarter loss of $0.19 per share, narrower than analysts’ expected $0.22 loss, on revenue of $33.55 million. It also raised its 2026 revenue guidance, offering a positive signal about its outlook. Alamar Q3 results and guidance
• Positive Sentiment: The company partnered with GSK on a large-scale study using Alamar’s NULISA platform to examine protein signatures across several disease areas. The collaboration could increase the platform’s visibility, though financial terms were not disclosed. GSK collaboration announcement
• Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study on neurodegenerative diseases, backed by major research organizations. It could showcase Alamar’s technology, although direct commercial benefits were not specified. UK Biobank study announcement
• Negative Sentiment: Major shareholder Corporate Gp VI Ltd. Qiming has disclosed repeated sales, including 43,930 shares on November 2 and 143,706 shares on October 30. Continued selling by a large holder may pressure sentiment; the filings do not give a reason for the transactions. SEC filing on shareholder sales

About Alamar Biosciences

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.